AngioDynamics
Builds vascular and oncology devices around atherectomy, thrombectomy, ablation, and access lines.
Something off on this page? Send us feedback.
Profile
Sells Med Tech platforms such as Auryon, AngioVac/AlphaVac, and NanoKnife alongside Med Device lines for venous care, ports, access, and other oncology uses. Sales are concentrated in the United States, and the portfolio is being narrowed toward higher-focus vascular and oncology platforms.
Provides vascular and oncology devices through a Med Tech segment built around Auryon for peripheral atherectomy, AngioVac and AlphaVac for thrombus removal, and NanoKnife for ablation. The remaining Med Device lines cover venous products, ports, access tools, and other oncology devices.
Revenue is concentrated in the United States, with international sales a smaller part of the mix. The company's execution focus is shifting from a broader catheter and vascular-access base toward differentiated platforms after divestitures and discontinued product lines.
The business depends on hospital procedure demand, physician adoption of named platforms, regulatory clearance for device indications, and competition from larger medical-device companies across vascular, oncology, and access markets.
Company facts
Categories
Key statistics
Year to date +25.1% · Average volume (30d) 413.0K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Jul 15, 2026 | H.C. Wainwright | Reiterate | Buy | $14 | $19 |
| Jul 15, 2026 | Canaccord Genuity | Reiterate | Buy | $18 | $20 |
| Oct 3, 2025 | Canaccord Genuity | Reiterate | Buy | $17 | $18 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Jul 14, 2026Q4 FY26 | −$0.11 | −$0.07 | +36.4% | $80.2M | $86.6M | +7.9% | +11.31% |
| Apr 2, 2026Q3 FY26 | −$0.11 | −$0.07 | +36.4% | $76.8M | $78.4M | +2.2% | −4.56% |
| Jan 6, 2026Q2 FY26 | −$0.10 | −$0.15 | −50.0% | $76.4M | $79.4M | +3.9% | −4.55% |
| Oct 2, 2025Q1 FY26 | −$0.14 | −$0.10 | +28.6% | $76.3M | $75.7M | −0.8% | −0.85% |
Financial highlights
| 12 quarters | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $72.0M | $80.2M | $75.7M | $79.4M | $78.4M | $86.6M | |
| Gross profit | $38.9M | $42.2M | $41.9M | $42.1M | $41.5M | $49.4M | |
| Operating income | −$10.0M | −$5.8M | −$10.7M | −$2.5M | −$6.4M | −$20.4M | |
| Net income | −$4.4M | −$6.1M | −$10.9M | −$6.4M | −$8.1M | −$11.4M | |
| Diluted EPS | −$0.11 | −$0.15 | −$0.26 | −$0.15 | −$0.19 | −$0.28 | |
| Gross margin | 54.0% | 52.7% | 55.3% | 53.1% | 52.9% | 57.1% | |
| Operating margin | -13.9% | -7.2% | -14.1% | -3.1% | -8.2% | -23.5% |
Fiscal years (4-quarter sums)FY22 $316.2M · FY23 $338.8M · FY24 $303.9M · FY25 $292.5M · FY26 $320.2M
Revenue by product · Q3 FY26
Revenue by geography · Q4 FY26
Balance sheet, May 31, 2026Cash & short-term investments $53.9M · Total debt $0 · Total assets $267.2M · Shareholders' equity $170.8M
Dividends
No dividends on record.
Ownership
Shares outstanding 41.33M · Float 36.54M · 88.4% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 3.80M | 9.20% | 13F | Aug 7, 2026 |
| Point72 Asset Management, L.P. | 3.06M | 7.41% | 13F | Aug 14, 2026 |
| Systematic Financial Management LP | 2.64M | 6.39% | 13F | Aug 14, 2026 |
| Kevin Kotler | 2.42M | 5.90% | 13G | Feb 9, 2026 |
| Armistice Capital, LLC | 2.20M | 5.32% | 13F | Aug 14, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jul 30, 2026 | Warren JR Nighan | officer: SVP Quality and Regulatory | −23,370 | $14.72 |
| Oct 21, 2025 | Lawrence T. Weiss | officer: SVP, Chief Legal Officer | +10,000 | $11.81 |
| Oct 13, 2025 | Stephen A. Trowbridge | officer: EVP and CFO | +890 | $11.16 |
| Oct 9, 2025 | James C. Clemmer | director, officer: President and CEO | +10,000 | $11.15 |
Peers
- Boston Scientific
Broadest overlap in PAD, thrombectomy, venous, and oncology tools
- Penumbra
Focused pressure in mechanical thrombectomy and PE/VTE clot removal
- Philips (ADR)
Laser and hybrid atherectomy overlap in PAD procedures
- Medtronic
PAD atherectomy and venous treatment overlap with vascular platforms
- Abbott
Peripheral artery disease portfolio overlaps Auryon and access devices
- BD
Major vascular access and implantable port competitor
- Merit Medical Systems
Interventional radiology peer across access, drainage, and dialysis
- Teleflex
Vascular access pressure through Arrow catheter and access lines
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| AngioDynamics | $15.85 | −0.06% | $655.1M | — | — | 2.0 | +8.1% |
| Boston Scientific | $46.85 | +0.03% | $69.62B | 19.0 | 14.2 | 3.3 | +7.5% |
| Penumbra | $321.68 | −0.05% | $12.67B | 79.0 | 58.1 | 8.4 | +14.9% |
| Philips (ADR) | $26.72 | +0.06% | $26.12B | 19.9 | 13.7 | 1.3 | −2.9% |
| Medtronic | $91.58 | +0.42% | $116.78B | 24.5 | 15.3 | 3.2 | +9.9% |
| Abbott | $112.20 | −0.22% | $194.62B | 36.2 | 19.4 | 4.2 | +13.0% |
| BD | $189.00 | −0.27% | $52.22B | 57.1 | 14.3 | 2.5 | −9.6% |
| Merit Medical Systems | $90.49 | +0.10% | $5.40B | 37.4 | 20.7 | 3.4 | +9.5% |
| Teleflex | $139.67 | −0.01% | $6.18B | — | 15.2 | 2.4 | −27.0% |
| Median | 36.2 | 15.2 | 3.3 | +8.5% |